Clinical Trial Update: Chemoprevention Trial in Familial Adenomatous Polyposis (FAP) Coli Using EPA [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluated eicosapentaenoic acid (EPA) for chemoprevention in familial adenomatous polyposis; results were posted after completion in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Adenomatous Polyposis

Drugs mentioned

• EPA (eicosapentaenoic acid) (eicosapentaenoic acid)

Snippet

Sponsor: S.L.A. Pharma AG | Conditions: Familial Adenomatous Polyposis Coli, FAP | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2014-08-22